Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL versus METRONIDAZOLE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL versus METRONIDAZOLE IN PLASTIC CONTAINER.
FLAGYL vs METRONIDAZOLE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
After intracellular reduction, metronidazole and its metabolites interact with DNA leading to inhibition of nucleic acid synthesis and cell death. It is active against anaerobic bacteria and protozoa.
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
500 mg IV every 8 hours or 7.5 mg/kg IV every 6 hours (loading dose 15 mg/kg) for most anaerobic infections.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
8 hours (range 6-12 hours) in adults with normal hepatic function; prolonged to 15-30 hours in severe liver disease
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (<5%)
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic